Best Pract & Res Clin Endocrin & Metabolism 2009
Las respuestas individuales varan
They focus on consistency
left alone, it can progress to MASH, fibrosis, and cirrhosis. Tirzepatide trials in MASLD/MASH show meaningful drops in liver fat, liver enzymes, and inflammatory changes on biopsy, with higher rates of NASH/MASH resolution and fibrosis improvement compared with placebo. Semaglutide also improves MASLD and MASH: phase 2 and phase 3 work, plus large realworld cohorts, link it to better liver histology, less fibrosis progression, and improved survival in MASLD patients versus controls. Both drugs are legitimate liverprotection tools in metabolic disease
Post-transcriptional mechanisms that regulate GPx-1 activity may prove to be crucial to maintaining cellular redox balance
Vagus nerve stimulation therapy is effective and safe for startle-induced seizures